Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calendula and chamomile for prevention and treatment of radiotherapy-induced skin irritation in head and neck cancer
RBR-8gxt823Not yet recruiting
- Sponsor
- Liga Contra o Câncer
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of calendula and chamomile in radiodermatitis (3 arms), sponsored by Liga Contra o Câncer. Primary endpoint: Radiodermatitis prevention. Planned start May 2025; status: not yet recruiting.
02
Drugs
calendulachamomile
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on RBR-8gxt823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8gxt823.